Ipsen SA is to acquire a privately-owned French biotech with an oncology product that has shown promise for patients with acute myeloid leukaemia (AML) not amenable to standard treatments. The target company, ImCheck Therapeutics SAS, has found of a way of simultaneously modulating the innate and adaptive immune systems with a monoclonal antibody, ICT01, that both identifies and kills cancer cells.
